Compare TG & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TG | VCRE |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 271.7M |
| IPO Year | 1994 | 2026 |
| Metric | TG | VCRE |
|---|---|---|
| Price | $7.73 | $9.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.16 |
| AVG Volume (30 Days) | ★ 174.6K | 25.3K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $800,821,000.00 | N/A |
| Revenue This Year | N/A | $101.29 |
| Revenue Next Year | N/A | $481.15 |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $6.25 | $7.88 |
| 52 Week High | $10.53 | $14.01 |
| Indicator | TG | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 40.94 |
| Support Level | $7.55 | $8.34 |
| Resistance Level | $8.10 | $12.08 |
| Average True Range (ATR) | 0.21 | 0.85 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 79.13 | 26.70 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.